8-K: Milestone Pharmaceuticals Resubmits NDA for Etripamil, Reports Q1 2024 Financials

Milestone Pharmaceuticals resubmitted its New Drug Application for etripamil for PSVT and reported its first quarter 2024 financial results, highlighting a strong cash position and progress in clinical development.

Summary

• Milestone Pharmaceuticals announced the resubmission of its New Drug Application (NDA) for etripamil for paroxysmal supraventricular tachycardia (PSVT) in the first quarter of 2024.
• The company had a productive meeting with the FDA regarding the Phase 3 protocol for etripamil in atrial fibrillation with rapid ventricular rate (AFib-RVR).
• Milestone closed a public offering of common shares and pre-funded warrants in March 2024, raising approximately $32.2 million in net proceeds.
• As of March 31, 2024, the company's cash, cash equivalents, and short-term investments totaled $89.5 million, compared to $66.0 million at the end of 2023.
• The company reported no revenue for the first quarter of 2024, compared to $1.0 million in the same period of 2023.
• Research and development expenses decreased to $3.6 million in Q1 2024 from $10.3 million in Q1 2023, primarily due to the completion of Phase 3 clinical studies for PSVT.
• The net loss for the first quarter of 2024 was $10.4 million, compared to a net loss of $15.0 million for the same period in 2023.
• The company expects its current cash resources to fund operations into 2026.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the resubmission of the NDA, strong cash position, and progress in clinical development. However, the lack of revenue and net loss temper the overall outlook.

Positives

• The resubmission of the NDA for etripamil for PSVT is a significant step towards potential approval.
• The company has a strong cash position of $89.5 million, expected to fund operations into 2026.
• The FDA has provided clear guidance on the Phase 3 study design for etripamil in AFib-RVR.
• Clinical data supports the efficacy of etripamil in converting PSVT.
• The company successfully raised $32.2 million in a public offering.
• The company is on track for potential FDA approval of CARDAMYST in the first half of 2025.

Negatives

• The company reported no revenue for the first quarter of 2024.
• The company experienced a net loss of $10.4 million for the first quarter of 2024.
• Commercial expenses increased to $2.9 million in Q1 2024 from $2.4 million in Q1 2023.

Risks

• The FDA may require additional trials or data, which could delay or jeopardize the approval of etripamil.
• The company's ability to successfully commercialize etripamil depends on regulatory approval and market acceptance.
• The company's future synthetic royalty payment is not guaranteed.
• The company is subject to general economic, political, and market conditions, including inflation and geopolitical events.
• The company's ability to raise additional capital in the current economic climate is uncertain.

Future Outlook

Milestone expects its current cash position, along with a potential future synthetic royalty payment, to fund the launch of CARDAMYST in the U.S. market for PSVT and anticipates potential FDA approval in the first half of 2025. The company also plans to finalize the Phase 3 protocol for etripamil in AFib-RVR in the second half of 2024.

Management Comments

• Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals, stated that they are on track for potential FDA approval of CARDAMYST in the first half of 2025.
• Joseph Oliveto also mentioned that the company remains focused on working with the FDA through the review process and preparing for commercialization and launch readiness.

Industry Context

This announcement is significant in the context of the cardiovascular therapeutics market, where there is a need for effective and convenient treatments for conditions like PSVT and AFib-RVR. The resubmission of the NDA and progress in clinical development position Milestone as a potential player in this space.

Comparison to Industry Standards

• The reported 60% conversion rate of PSVT within 30 minutes and 69.9% within 60 minutes with etripamil is comparable to or better than some existing treatments for acute PSVT episodes, such as intravenous adenosine or verapamil, which often require medical supervision.
• The development of a self-administered nasal spray for PSVT and AFib-RVR is a novel approach, contrasting with traditional treatments that often require hospital visits or invasive procedures. This positions Milestone as a potential disruptor in the market.
• Companies like BioMarin Pharmaceutical and Amgen have also focused on developing novel therapies for cardiovascular conditions, but Milestone's focus on self-administered treatments for episodic events is a unique approach.
• The cash runway into 2026 is a positive sign, as many biotech companies struggle with funding, especially during the clinical development phase. This is comparable to companies like Alnylam Pharmaceuticals, which have secured significant funding to support their research and development efforts.

Stakeholder Impact

• Shareholders are positively impacted by the progress in clinical development and the company's strong cash position.
• Patients with PSVT and AFib-RVR may benefit from a new, self-administered treatment option.
• Employees are likely to be impacted by the company's continued growth and development.
• The company's suppliers and creditors are likely to be impacted by the company's financial performance and future plans.

Next Steps

• Milestone will continue to work with the FDA through the NDA review process for etripamil in PSVT.
• The company will communicate further with the FDA in the second half of 2024 to finalize the Phase 3 protocol for etripamil in AFib-RVR.
• Milestone will prepare for the potential commercialization and launch of CARDAMYST in the U.S. market.

Key Dates

Keywords

etripamil, PSVT, AFib-RVR, NDA, FDA, cardiovascular, clinical trials, biopharmaceutical, nasal spray, arrhythmia